MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
Want to see MBX full AI Analyst Report?
Top Page
MBX Biosciences, Inc.
(NASDAQ:MBX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$32.00
▼(-5.24% Downside)
Action:Reiterated
Date:05/12/26
Score is held back primarily by weak fundamentals typical of a development-stage biotech—no revenue, widening losses, and worsening cash burn—despite a low-debt, improved balance sheet. Offsetting factors include strong recent price momentum and multiple positive pipeline/regulatory events, while valuation remains constrained by losses and the lack of a dividend.
Positive Factors
Low leverage and stronger capital base
Very low debt and a materially improved equity base reduce solvency risk and increase strategic flexibility. A stronger balance sheet supports continued R&D spending, partnering optionality, and resilience during clinical development, lengthening the runway for pivotal programs.
Negative Factors
Pre-revenue with widening losses
Being pre-revenue with rapidly growing operating losses means the company currently cannot self-fund commercialization. Persistent negative profitability erodes shareholder value over time and increases reliance on external financing or partnerships to advance late-stage programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger capital base
Very low debt and a materially improved equity base reduce solvency risk and increase strategic flexibility. A stronger balance sheet supports continued R&D spending, partnering optionality, and resilience during clinical development, lengthening the runway for pivotal programs.
Read all positive factors
MBX Biosciences, Inc. (MBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47B
Dividend YieldN/A
Average Volume (3M)606.98K
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue GrowthN/A
EPS Growth-0.43%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.20
Shares Outstanding47,597,534
10 Day Avg. Volume913,198
30 Day Avg. Volume606,976
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.36K
Enterprise Value/Ebitda-10.14
Forecast
1Y Price Target
$73.11Price Target Upside116.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
MBX Biosciences, Inc. Business Overview & Revenue Model
Company Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroi...
How the Company Makes Money
null...
MBX Biosciences, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -224.00K | -248.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -96.31M | -98.06M | -67.95M | -35.15M | -25.70M |
| Net Income | -86.61M | -86.97M | -61.92M | -32.56M | -26.14M |
Balance Sheet | |||||
| Total Assets | 452.70M | 385.14M | 268.54M | 84.18M | 45.09M |
| Cash, Cash Equivalents and Short-Term Investments | 439.98M | 373.70M | 262.15M | 80.68M | 42.46M |
| Total Debt | 555.00K | 596.00K | 171.00K | 324.00K | 461.00K |
| Total Liabilities | 14.95M | 15.92M | 11.09M | 156.65M | 87.70M |
| Stockholders Equity | 437.76M | 369.22M | 257.44M | -72.47M | -42.60M |
Cash Flow | |||||
| Free Cash Flow | -79.81M | -81.88M | -55.55M | -32.11M | -23.56M |
| Operating Cash Flow | -77.48M | -79.95M | -54.68M | -31.98M | -23.12M |
| Investing Cash Flow | -184.03M | -83.70M | -160.59M | -30.93M | -11.41M |
| Financing Cash Flow | 277.02M | 189.59M | 234.10M | 69.22M | 46.06M |
MBX Biosciences, Inc. Risk Analysis
MBX Biosciences, Inc. disclosed 93 risk factors in its most recent earnings report. MBX Biosciences, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MBX Biosciences, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.47B | -14.78 | -24.50% | ― | ― | -0.43% | |
56 Neutral | $1.42B | -47.34 | -1057.44% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.12B | -15.04 | -42.66% | ― | ― | -33.07% | |
46 Neutral | $1.60B | -5.04 | -64.21% | ― | 27.23% | -12.53% | |
43 Neutral | $45.23M | -0.41 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
MBX
MBX Biosciences, Inc.
30.39
18.03
145.87%
KALV
KalVista Pharmaceuticals
26.77
14.53
118.71%
GOSS
Gossamer Bio
0.20
-0.98
-83.14%
NRIX
Nurix Therapeutics
15.24
5.10
50.30%
TYRA
Tyra Bioscience
33.78
23.80
238.48%
MBX Biosciences, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
MBX Biosciences Highlights Positive Phase 1 Obesity Data
Positive
May 11, 2026
On May 11, 2026, MBX Biosciences reported preliminary blinded Phase 1 data for its dual GLP-1/GIP prodrug MBX 4291 in adults with obesity, showing dose-proportional pharmacokinetics, a slow-release profile compatible with once-monthly dosing, and ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
MBX Biosciences Advances Canvuparatide After Phase 2 FDA Meeting
Positive
Mar 9, 2026
On March 9, 2026, MBX Biosciences reported that it had successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on its once-weekly parathyroid hormone prodrug canvuparatide for chronic hypoparathyroidism. The FDA...
Business Operations and StrategyExecutive/Board Changes
MBX Biosciences Announces CFO Transition and Interim Appointment
Positive
Feb 27, 2026
On February 24, 2026, MBX Biosciences, Inc. signed a lease with 5 Burlington Woods, LLC for about 13,642 square feet of new office and lab space in Burlington, Mass., with a four-year term beginning five months after an expected May 1, 2026 commen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.